Which has higher earnings & valuation, NVO or ARGX?

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.81 $15.51B $4.26 11.83 argenex $4.25B 13.76 $1.29B $22.46 41.84

Is NVO or ARGX more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% argenex 31.31% 44.37% 37.55%

Does the media favor NVO or ARGX?

In the previous week, Novo Nordisk A/S had 34 more articles in the media than argenex. MarketBeat recorded 37 mentions for Novo Nordisk A/S and 3 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.98 beat argenex's score of 0.33 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 24 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ARGX or GSK?

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.76 $1.29B $22.46 41.84 GSK $43.07B 2.52 $7.54B $3.85 13.94

Is ARGX or GSK more profitable?

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% GSK 17.82% 44.28% 11.49%

Does the media prefer ARGX or GSK?

In the previous week, argenex had 1 more articles in the media than GSK. MarketBeat recorded 3 mentions for argenex and 2 mentions for GSK. GSK's average media sentiment score of 0.36 beat argenex's score of 0.33 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, SNY or ARGX?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.12 $8.84B $3.58 12.06 argenex $4.25B 13.76 $1.29B $22.46 41.84

Is SNY or ARGX more profitable?

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% argenex 31.31% 44.37% 37.55%

Does the media favor SNY or ARGX?

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 4 mentions for Sanofi and 3 mentions for argenex. argenex's average media sentiment score of 0.33 beat Sanofi's score of -0.06 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAK or ARGX?

argenex has a consensus price target of $1,034.56, suggesting a potential upside of 10.10%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 argenex 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.92

Does the media refer more to TAK or ARGX?

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than argenex. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 3 mentions for argenex. argenex's average media sentiment score of 0.33 beat Takeda Pharmaceutical's score of 0.15 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RVMD or ARGX?

In the previous week, Revolution Medicines had 13 more articles in the media than argenex. MarketBeat recorded 16 mentions for Revolution Medicines and 3 mentions for argenex. Revolution Medicines' average media sentiment score of 0.79 beat argenex's score of 0.33 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

argenex (ARGX) Competitors

$939.68 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$944.36 +4.68 (+0.50%)

As of 06:51 AM Eastern

Compare

ARGX vs. NVO, GSK, SNY, TAK, and RVMD

Should you buy argenex stock or one of its competitors? MarketBeat compares argenex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with argenex include Novo Nordisk A/S (NVO), GSK (GSK), Sanofi (SNY), Takeda Pharmaceutical (TAK), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does argenex compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Novo Nordisk A/S currently has a consensus target price of $65.56, suggesting a potential upside of 30.12%. argenex has a consensus target price of $1,034.56, suggesting a potential upside of 10.10%. Given Novo Nordisk A/S's higher probable upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
argenex	31.31%	44.37%	37.55%

Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.81	$15.51B	$4.26	11.83
argenex	$4.25B	13.76	$1.29B	$22.46	41.84

In the previous week, Novo Nordisk A/S had 34 more articles in the media than argenex. MarketBeat recorded 37 mentions for Novo Nordisk A/S and 3 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.98 beat argenex's score of 0.33 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	24 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

argenex beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

How does argenex compare to GSK?

argenex (NASDAQ:ARGX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.76	$1.29B	$22.46	41.84
GSK	$43.07B	2.52	$7.54B	$3.85	13.94

argenex presently has a consensus price target of $1,034.56, indicating a potential upside of 10.10%. GSK has a consensus price target of $53.00, indicating a potential downside of 1.28%. Given argenex's stronger consensus rating and higher possible upside, equities analysts plainly believe argenex is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
GSK	17.82%	44.28%	11.49%

argenex has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

60.3% of argenex shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, argenex had 1 more articles in the media than GSK. MarketBeat recorded 3 mentions for argenex and 2 mentions for GSK. GSK's average media sentiment score of 0.36 beat argenex's score of 0.33 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

argenex beats GSK on 13 of the 17 factors compared between the two stocks.

How does argenex compare to Sanofi?

Sanofi (NASDAQ:SNY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.06
argenex	$4.25B	13.76	$1.29B	$22.46	41.84

Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 44.37% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
argenex	31.31%	44.37%	37.55%

Sanofi currently has a consensus price target of $51.00, suggesting a potential upside of 18.16%. argenex has a consensus price target of $1,034.56, suggesting a potential upside of 10.10%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 4 mentions for Sanofi and 3 mentions for argenex. argenex's average media sentiment score of 0.33 beat Sanofi's score of -0.06 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

argenex beats Sanofi on 12 of the 16 factors compared between the two stocks.

How does argenex compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 44.37% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
argenex	31.31%	44.37%	37.55%

argenex has a consensus price target of $1,034.56, suggesting a potential upside of 10.10%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than argenex. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 3 mentions for argenex. argenex's average media sentiment score of 0.33 beat Takeda Pharmaceutical's score of 0.15 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

argenex has lower revenue, but higher earnings than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.88	-$1.01B	$0.39	42.91
argenex	$4.25B	13.76	$1.29B	$22.46	41.84

Summary

argenex beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does argenex compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, argenex has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,474.30	-$1.13B	-$7.07	N/A
argenex	$4.25B	13.76	$1.29B	$22.46	41.84

argenex has a net margin of 31.31% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 44.37% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
argenex	31.31%	44.37%	37.55%

In the previous week, Revolution Medicines had 13 more articles in the media than argenex. MarketBeat recorded 16 mentions for Revolution Medicines and 3 mentions for argenex. Revolution Medicines' average media sentiment score of 0.79 beat argenex's score of 0.33 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines currently has a consensus price target of $135.39, indicating a potential downside of 28.46%. argenex has a consensus price target of $1,034.56, indicating a potential upside of 10.10%. Given argenex's higher possible upside, analysts plainly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

Get argenex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARGX vs. The Competition

Export

Metric	argenex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.44B	$3.76B	$6.98B	$12.46B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	41.84	21.80	27.78	24.70
Price / Sales	13.76	326.25	534.41	98.72
Price / Cash	44.05	64.18	29.65	49.23
Price / Book	7.94	8.67	11.04	6.49
Net Income	$1.29B	$23.68M	$3.57B	$336.25M
7 Day Performance	2.98%	1.23%	1.15%	0.35%
1 Month Performance	5.43%	13.43%	6.08%	3.91%
1 Year Performance	72.95%	62.61%	33.32%	23.88%

argenex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARGX argenex	3.9892 of 5 stars	$939.68 flat	$1,034.56 +10.1%	+73.0%	$58.44B	$4.25B	41.84	1,863
NVO Novo Nordisk A/S	4.1769 of 5 stars	$48.36 +0.6%	$65.56 +35.6%	-27.0%	$214.63B	$327.80B	11.35	69,505	Trending News
GSK GSK	3.044 of 5 stars	$52.87 +0.7%	$53.00 +0.3%	+40.3%	$106.32B	$43.07B	13.74	66,841	Dividend Cut Gap Down
SNY Sanofi	4.4069 of 5 stars	$43.43 +1.1%	$51.00 +17.4%	-11.7%	$104.13B	$49.35B	12.13	74,846
TAK Takeda Pharmaceutical	2.4423 of 5 stars	$15.97 +0.3%	N/A	+7.6%	$50.63B	$28.32B	40.94	47,455	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARGX) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Competitors

ARGX vs. NVO, GSK, SNY, TAK, and RVMD

How does argenex compare to Novo Nordisk A/S?

Summary

How does argenex compare to GSK?

Summary

How does argenex compare to Sanofi?

Summary

How does argenex compare to Takeda Pharmaceutical?

Summary

How does argenex compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Competitors

ARGX vs. NVO, GSK, SNY, TAK, and RVMD

How does argenex compare to Novo Nordisk A/S?

Do analysts prefer NVO or ARGX?

Is NVO or ARGX more profitable?

Which has more volatility and risk, NVO or ARGX?

Which has higher earnings & valuation, NVO or ARGX?

Does the media favor NVO or ARGX?

Do institutionals & insiders hold more shares of NVO or ARGX?

Summary

How does argenex compare to GSK?

Which has higher earnings and valuation, ARGX or GSK?

Do analysts recommend ARGX or GSK?

Is ARGX or GSK more profitable?

Which has more volatility and risk, ARGX or GSK?

Do institutionals and insiders have more ownership in ARGX or GSK?

Does the media prefer ARGX or GSK?

Summary

How does argenex compare to Sanofi?

Do insiders & institutionals hold more shares of SNY or ARGX?

Which has better valuation and earnings, SNY or ARGX?

Which has more volatility and risk, SNY or ARGX?

Is SNY or ARGX more profitable?

Do analysts rate SNY or ARGX?

Does the media favor SNY or ARGX?

Summary

How does argenex compare to Takeda Pharmaceutical?

Do institutionals & insiders hold more shares of TAK or ARGX?

Is TAK or ARGX more profitable?

Do analysts rate TAK or ARGX?

Does the media refer more to TAK or ARGX?

Which has more risk and volatility, TAK or ARGX?

Which has preferable valuation & earnings, TAK or ARGX?

Summary

How does argenex compare to Revolution Medicines?

Which has more risk and volatility, RVMD or ARGX?

Which has stronger valuation and earnings, RVMD or ARGX?

Is RVMD or ARGX more profitable?

Does the media favor RVMD or ARGX?

Do insiders and institutionals believe in RVMD or ARGX?

Do analysts prefer RVMD or ARGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools